Inhibrx delivers ‘differentiated’ cancer drug data; Fractyl starts diabetes gene therapy trial

Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy

Inhibrx Biosciences’ INBRX-106 Combo Tops KEYTRUDA Alone in Phase 2 Cancer Study

Should Positive INBRX-106 Phase 2 Head and Neck Data Require Action From Inhibrx Biosciences (INBX) Investors?

Inhibrx Reports First Quarter 2026 Financial Results

Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma

Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study

Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study

Inhibrx Shares Rise After Positive Phase 2 Head and Neck Cancer Data

Inhibrx Founder and CEO Mark Lappe Buys 25,000 Shares for $2.6 Million. What Does His Confidence Tell Investors?